The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene:
##STR1##
and pharmaceutical compositions thereof. The present invention in particular
is directed to the L-tartrate salt, and further to the various polymorphs of the
L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein
as Forms A and B) and a hydrate polymorph (referred to herein as Form C). In addition,
the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
and the various polymorphs thereof; as well as the D,L-tartrate salt thereof and
its polymorphs, and the meso-tartrate salt thereof and its polymorphs.
